Crestor Gets Advisory Committee For Preventing Cardiovascular Events
This article was originally published in The Pink Sheet Daily
Executive Summary
If AstraZeneca gets JUPITER results on label, it could improve reimbursement for the indication in patients with healthy cholesterol levels but biomarker for inflammation and at least one CVD risk factor.
You may also be interested in...
Simcere Acquires Manufacturing Rights For Generic Crestor In China; Hopes Sales Force Will Provide Edge Over Competition
SHANGHAI - Chinese firm Simcere signed an agreement with Tianjin Tianda Pharmaceutical to acquire the manufacturing license in China for Tianda's rosuvastatin, a generic version of AstraZeneca's cholesterol and atherosclerosis treatment Crestor (rosuvastatin), Simcere announced Nov. 9
CBO Doubts Aside, Wellness And Prevention Look Strong In Health Reform
Under CBO's budget scorekeeping rules, prevention and wellness activities do not produce sufficiently demonstrable and quantifiable savings in the near term to qualify as offsets to appropriations, but a general cost-benefit analysis more accurately reflects the costs and benefits of interventions, experts say.
Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting
Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.